These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 9126846)
1. Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries. Ditzel HJ; Parren PW; Binley JM; Sodroski J; Moore JP; Barbas CF; Burton DR J Mol Biol; 1997 Apr; 267(3):684-95. PubMed ID: 9126846 [TBL] [Abstract][Full Text] [Related]
2. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. Ditzel HJ; Binley JM; Moore JP; Sodroski J; Sullivan N; Sawyer LS; Hendry RM; Yang WP; Barbas CF; Burton DR J Immunol; 1995 Jan; 154(2):893-906. PubMed ID: 7529290 [TBL] [Abstract][Full Text] [Related]
3. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935 [TBL] [Abstract][Full Text] [Related]
4. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527 [TBL] [Abstract][Full Text] [Related]
5. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015 [TBL] [Abstract][Full Text] [Related]
6. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1. Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420 [TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs. Koefoed K; Farnaes L; Wang M; Svejgaard A; Burton DR; Ditzel HJ J Immunol Methods; 2005 Feb; 297(1-2):187-201. PubMed ID: 15777942 [TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein. Shotton C; Arnold C; Sattentau Q; Sodroski J; McKeating JA J Virol; 1995 Jan; 69(1):222-30. PubMed ID: 7527084 [TBL] [Abstract][Full Text] [Related]
9. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries. Boots LJ; McKenna PM; Arnold BA; Keller PM; Gorny MK; Zolla-Pazner S; Robinson JE; Conley AJ AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1549-59. PubMed ID: 9430247 [TBL] [Abstract][Full Text] [Related]
10. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. McKeating JA; Shotton C; Cordell J; Graham S; Balfe P; Sullivan N; Charles M; Page M; Bolmstedt A; Olofsson S J Virol; 1993 Aug; 67(8):4932-44. PubMed ID: 7687306 [TBL] [Abstract][Full Text] [Related]
11. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities. Alsmadi O; Tilley SA J Virol; 1998 Jan; 72(1):286-93. PubMed ID: 9420226 [TBL] [Abstract][Full Text] [Related]
12. Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque. Glamann J; Burton DR; Parren PW; Ditzel HJ; Kent KA; Arnold C; Montefiori D; Hirsch VM J Virol; 1998 Jan; 72(1):585-92. PubMed ID: 9420262 [TBL] [Abstract][Full Text] [Related]
13. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120. Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576 [TBL] [Abstract][Full Text] [Related]
14. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095 [TBL] [Abstract][Full Text] [Related]
15. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. He Y; Honnen WJ; Krachmarov CP; Burkhart M; Kayman SC; Corvalan J; Pinter A J Immunol; 2002 Jul; 169(1):595-605. PubMed ID: 12077293 [TBL] [Abstract][Full Text] [Related]
16. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy. Zvi A; Feigelson DJ; Hayek Y; Anglister J Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308 [TBL] [Abstract][Full Text] [Related]
17. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. Stamatatos L; Cheng-Mayer C J Virol; 1995 Oct; 69(10):6191-8. PubMed ID: 7545244 [TBL] [Abstract][Full Text] [Related]
18. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein. Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203 [TBL] [Abstract][Full Text] [Related]
19. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. Moore JP; Sattentau QJ; Yoshiyama H; Thali M; Charles M; Sullivan N; Poon SW; Fung MS; Traincard F; Pinkus M J Virol; 1993 Oct; 67(10):6136-51. PubMed ID: 7690418 [TBL] [Abstract][Full Text] [Related]
20. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. Acharya P; Tolbert WD; Gohain N; Wu X; Yu L; Liu T; Huang W; Huang CC; Kwon YD; Louder RK; Luongo TS; McLellan JS; Pancera M; Yang Y; Zhang B; Flinko R; Foulke JS; Sajadi MM; Kamin-Lewis R; Robinson JE; Martin L; Kwong PD; Guan Y; DeVico AL; Lewis GK; Pazgier M J Virol; 2014 Nov; 88(21):12895-906. PubMed ID: 25165110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]